Barclays’s BeOne Medicines ONC Stock Holding History
Bought
Maintained
Sold
Other funds holding ONC
BBA
Barclays's ONC Position: Q3 2026 in Review
Barclays reduced its BeOne Medicines (ONC) stake by 27% in Q3 2026, selling an estimated $2.52M and leaving 20,335 shares worth $7.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1825.
Barclays first reported a position in ONC in Q4 2016 and has held it in 40 quarters since. The position peaked at $19.7M in Q4 2020. 325 funds tracked by Wall St. Rank hold ONC as of Q3 2026.
- Barclays held 20,335 shares of BeOne Medicines worth $7.44M as of Q3 2026.
- Barclays sold 7,381 BeOne Medicines shares in Q3 2026, an estimated $2.52M.
- BeOne Medicines made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1825 holding.
- Barclays first reported a position in BeOne Medicines in Q4 2016 and has held it in 40 quarters since.
- Barclays's BeOne Medicines position peaked at $19.7M in Q4 2020.
- 325 funds tracked by Wall St. Rank held BeOne Medicines as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.